GlassScriptPhysician profile
Arup Paul
NPI 1033781141
$6,126.71
in general payments reported to CMS, 2019-2025
20 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,991 · 2023: $1,971 · 2024: $2,040 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,051.74 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,241.52 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $965.94 | 2022-2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $687.99 | 2022-2024 | Epclusa |
| Janssen Biotech, INC. | $626.97 | 2023-2024 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $447.17 | 2022-2024 | Dupixent |
| Genzyme Corporation | $158.60 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $132.96 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $132.75 | 2024 | Injectafer |
| Endogastric Solutions, INC | $125.70 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $124.89 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $119.92 | 2022-2024 | Entyvio, Gattex |
| Qol Medical, LLC | $86.87 | 2022-2024 | Sucraid |
| Redhill Biopharma INC. | $57.13 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $53.82 | 2022-2024 | |
| Lilly USA, LLC | $51.72 | 2023-2024 | Omvoh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.32 | 2022 | |
| Dexcom, INC. | $24.67 | 2024 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $21.39 | 2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $21.25 | 2024 | Bylvay |
| Intercept Pharmaceuticals, INC. | $20.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arup Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.